re: the big biotech hope
The competitive position for CST's QFT-G is an interesting one.
The old TST is still by far the biggest competitor, and has enormous momentum by virtue of its 115 years of use. There is a lesson here - if QFT-G establishes market dominance, they will probably be very hard to displace.
Elispot (the experimental product) and T-Spot (the commercial product) are not quite identical, despite the efforts of the developer, Oxford Immunotech, to have them viewed that way. So the FDA may require that all the testing be done on T-Spot before they will approve it. To date, there has been about ten times as much work published on QFT-G as on T-Spot, so there is a long way for the latter to go - and in this industry, "a long way" means two to four YEARS.
So the "competitors" are a very old incumbent (which gives frequent, expensive, false positives, and is technically inferior) and a test (T-Spot) which is equally as effective as QFT-G, but is much more expensive, more difficult to use, and probably still far away from gaining key approvals.
In strict literal sense, it is clearly nonsense to say that there are no competitors. But in the real, practical world, that just about describes the effective situation.
CST Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
